Fed, Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Subjects

Therapeutic Equivalency Clinical Trial

Official title:

A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Normal Healthy Non-Smoking Male and Female Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00648544
• Other study ID #: 2722
• Status: Completed
• Phase: Phase 1
• Start date: July 2003
• Est. completion date: July 2003

Study information

• Verified date: April 2024
• Source: Viatris Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study was designed to compare the rate and extent of absorption of pravastatin sodium from the following formulations under fed conditions:

1. Pravastatin Sodium 80 mg Tablets (Genpharm Inc. Canada)

2. Pravachol® 80 mg Tablets (Bristol-Myers Squibb Co., U.S.A.) Bioequivalence of these formulations was assessed for pravastatin.

Based on the results from this study, these two 80 mg pravastatin tablet formulations demonstrated bioequivalence under the single-dose fed conditions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: July 2003
• Est. primary completion date: July 2003
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects meeting the following criteria may be included in the study:

• Non-smoking male or female with a minimum age of 18 years.

• Body Mass Index (BMI = weight/height2) greater than or equal to 19 kg/m2 and less than or equal to 26 kg/m2.

• Availability of subject for the entire study period and willingness to adhere to protocol requirements, as evidenced by a signed Informed Consent Form.

• Normal findings in the physical examination, 12-lead ECG and vital signs (blood pressure between 100-140/60-90 mmHg, heart rate between 50-99 beats/min and temperature between 35.8°C and 37.5°C).

• Negative for drugs of abuse, nicotine , alcohol, hepatitis B-surface antigen, hepatitis C and HIV, and for female subjects, pregnancy (serum ß-CG).

• No clinical laboratory values outside of the acceptable range as defined by BCR, unless the Principal Investigator decides they are not clinically significant.

• Female subjects who are surgically sterile for at least six months or post-menopausal for at least one year, or who will avoid pregnancy prior to the study, during the study and up until one month after the end of the study.

Exclusion Criteria:

• Subjects meeting any of the following criteria will be excluded:

• Known history of hypersensitivity to pravastatin sodium (e.g. Pravachol®, Lipostat®) and/or related drugs such as simvastatin (Zocor®), atorvastatin (Lipitor™), cerivastatin (Baycol®) or fluvastatin (Lescol®).

• Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal, neurological, hematological, liver or kidney disease, unless judged not clinically significant by the Principal Investigator, or medical designate.

• Known history or presence of food allergies, or any condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.

• Any clinically significant illness during the last four weeks prior to entry into this study.

• Presence of any significant physical or organ abnormality.

• Any subject with a history of drug abuse.

• Any psychiatric or psychological disease (including depression) unless deemed not clinically significant by the Principal Investigator, or medical designate.

• Use of any prescription medication within 14 days preceding entry into this study.

• Use of over-the-counter (OTC) medication within seven days preceding entry into this study (except for spermicidal/barrier contraceptive products).

• Female subjects: use of oral contraceptives or contraceptive implants (such as Norplant®) within 30 days prior to drug administration or a depot injection of progestogen drug (e.g. Depo-Provera®) within one year prior to drug administration.

• Female subjects: presence of pregnancy or lactation.

• Any subject who has had blood withdrawals within 56 days preceding this study, taken during the conduct of any clinical study at a facility other than BCR, or within the lockout period specified by a previous study conducted at BCR.

• Participation in a clinical trial with an investigational drug within 30 days preceding this study.

• Any subject who has donated blood within 56 days preceding this study.

• Any subject who has participated as a plasma donor in a plasmapheresis program within seven days preceding this study.

• Significant or recent history of asthma (after 12 years of age).

• Any subject with a recent (less than one year) history of alcohol abuse.

Related Conditions & MeSH terms

• Therapeutic Equivalency

Intervention

Drug:
• Pravastatin
Single-dose 80 mg oral immediate-release tablet
• Pravastatin
Single-dose 80 mg oral immediate-release tablets

Locations

Country	Name	City	State
Canada	Biovail Contract Reseach	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Mylan Pharmaceuticals Inc	Genpharm ULC

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Therapeutic Bioequivalence		Within 30 days

External Links

•   Daily Med - posting of most recent submitted labelling to the Food and Drug Administration (FDA) and currently in use
•   Mylan Pharmaceuticals Inc. - Clinical Trial Results
•   Recalls, Market Withdrawals and Safety Alerts